scispace - formally typeset
W

Weiguo Cao

Researcher at Shanghai University

Publications -  343
Citations -  5265

Weiguo Cao is an academic researcher from Shanghai University. The author has contributed to research in topics: Aryl & Catalysis. The author has an hindex of 35, co-authored 333 publications receiving 4686 citations. Previous affiliations of Weiguo Cao include Shanghai Jiao Tong University & University of Toronto.

Papers
More filters
Journal ArticleDOI

Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents

TL;DR: The development of porphysomes; nanovesicles formed from self-assembled porphyrin bilayers that generated large, tunable extinction coefficients, structure-dependent fluorescence self-quenching and unique photothermal and photoacoustic properties demonstrate the multimodal potential of organic nanoparticles for biophotonic imaging and therapy.
Journal ArticleDOI

Biomimetic Nanocarrier for Direct Cytosolic Drug Delivery

TL;DR: The ability to transport a large quantity of drug molecules into cytosolic compartments of cancer cells has powerful implications in modern molecular therapeutics because the sites of action of the drugs are often cytosol organelles.
Journal ArticleDOI

HDL-mimicking peptide-lipid nanoparticles with improved tumor targeting.

TL;DR: By adding targeting ligands to nanoparticles that mimic high-density lipoprotein (HDL), tumor-targeted sub-30-nm peptide-lipid nanocarriers are created with controllable size, cargo loading, and shielding properties.
Journal ArticleDOI

FRET Quenching of Photosensitizer Singlet Oxygen Generation

TL;DR: The presented findings show that FRET-based quenchers can potently decrease singlet oxygen production and therefore be used to facilitate the rational design of activatable photosensitizers.
Journal ArticleDOI

Ligand conjugated low-density lipoprotein nanoparticles for enhanced optical cancer imaging in vivo.

TL;DR: A ligand-conjugated, NIR-labeled LDL is synthsized that enables the first in vivo demonstration of rerouting LDL from LDL receptors to selected alternate receptors, thus drastically expanding the range of using LDL particles as nanocarriers for in vivo cancer imaging and treatment.